DEPO has seen a 20% decline after releasing Q1 results that came in below expectations However, these results were impacted by accounting …
In a research report published Friday, Roth Capital analyst Scott Henry upgraded shares of Depomed (NASDAQ:DEPO) from a Neutral to a Buy rating and …
Yesterday, Roth Capital analyst Scott Henry issued a note in which he reiterated a Neutral rating on Depomed Inc. (DEPO) with a $13.
